Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and ... Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.36 | -4.3530834341 | 8.27 | 8.399 | 7.81 | 630226 | 8.02515441 | CS |
| 4 | 0.41 | 5.46666666667 | 7.5 | 8.49 | 7.21 | 535962 | 7.93477101 | CS |
| 12 | -0.24 | -2.94478527607 | 8.15 | 8.95 | 7.21 | 440555 | 7.9798686 | CS |
| 26 | 0.01 | 0.126582278481 | 7.9 | 9.76 | 6.61 | 579764 | 8.21272295 | CS |
| 52 | 2.17 | 37.8048780488 | 5.74 | 9.76 | 4.2 | 584502 | 7.4486337 | CS |
| 156 | 2.26 | 40 | 5.65 | 9.76 | 3.89 | 402400 | 6.81561607 | CS |
| 260 | 2.26 | 40 | 5.65 | 9.76 | 3.89 | 402400 | 6.81561607 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
